title: Malariological baseline survey and in vitro antimalarial drug resistance in Gulu district, Northern Uganda.
abstract: A comprehensive, representative malaria survey has been carried out in a population of internally displaced persons (IDP) in the district of Gulu, Northern Uganda. It included 74 households and 390 persons, and covered socio-economic and environmental information, individual physical data, malaria and the drug sensitivity of Plasmodium falciparum. The prevalence of infections with Plasmodium falciparum was 54.4% at a geometric mean asexual parasitaemia of 229/microl blood, typical for hyperendemic conditions. P. falciparum turned out to be highly resistant to chloroquine and amodiaquine. It showed also reduced sensitivity against lumefantrine and artemisinin, obviously the result of the liberal use of the lumefantrine-artemether combination without evidence-based indication.
authors.affiliation: Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany.
authors.forename: Christof
authors.initials: C
authors.lastname: Prugger
authors.forename: Michael
authors.initials: M
authors.lastname: Engl
authors.forename: Martin
authors.initials: M
authors.lastname: Ogwang
authors.forename: Franz
authors.initials: F
authors.lastname: Ploner
authors.forename: Martin
authors.initials: M
authors.lastname: Ploner
authors.forename: Doris
authors.initials: D
authors.lastname: Gluderer
authors.forename: Gunther
authors.initials: G
authors.lastname: Wernsdorfer
authors.forename: Walther H
authors.initials: WH
authors.lastname: Wernsdorfer
mesh_terms: D000293:Adolescent; D000328:Adult; D000655:Amodiaquine / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000962:Antimalarials / Q000494:pharmacology / Q000627:therapeutic use*; D037621:Artemisinins / Q000494:pharmacology / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002738:Chloroquine / Q000494:pharmacology / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D003906:Developing Countries; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D019353:Endemic Diseases; D004983:Ethanolamines / Q000494:pharmacology / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D005260:Female; D005449:Fluorenes / Q000494:pharmacology / Q000627:therapeutic use; D006306:Health Surveys; D006801:Humans; D015994:Incidence; D007223:Infant; D000078102:Lumefantrine; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000453:epidemiology*; D008297:Male; D021261:Parasitic Sensitivity Tests; D010963:Plasmodium falciparum / Q000187:drug effects*; D012036:Refugees / Q000706:statistics & numerical data*; D014454:Uganda; D055815:Young Adult
chemical_list: D000962:Antimalarials; D037621:Artemisinins; D004983:Ethanolamines; D005449:Fluorenes; D000655:Amodiaquine; D002738:Chloroquine; C031327:artemisinin; D000078102:Lumefantrine